Hypopharyngeal cancer: A state of the art review
•Hypopharyngeal squamous cell carcinoma has a reported 5-year overall survival rate of approximately 30–35%.•Nearly 50% of patients exhibitrecurrence within the first year after diagnosis.•Laryngeal preservation strategies are well supported although long term toxicity is significant.•Salvage surger...
Gespeichert in:
| Veröffentlicht in: | Oral oncology 2018-11, Vol.86, p.244-250 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 250 |
|---|---|
| container_issue | |
| container_start_page | 244 |
| container_title | Oral oncology |
| container_volume | 86 |
| creator | Garneau, Jonathan C. Bakst, Richard L. Miles, Brett A. |
| description | •Hypopharyngeal squamous cell carcinoma has a reported 5-year overall survival rate of approximately 30–35%.•Nearly 50% of patients exhibitrecurrence within the first year after diagnosis.•Laryngeal preservation strategies are well supported although long term toxicity is significant.•Salvage surgery a common occurrence.•Future directions will focus on immunotherapy/targeted therapies to improve survival outcomes.
Cancer of the hypopharynx is relatively rare and accounts for roughly 3% of all head and neck cancers. Unfortunately, hypopharyngeal carcinoma has one of the worst prognosis of all head and neck cancers with a reported 5-year overall survival rate of approximately 30–35%. Toxicity related to therapy, and the need for surgical salvage continue to dominate the landscape in this disease. In this article, we set out to discuss a comprehensive overview of the current management principles, recent literature and evidence based therapeutic options surrounding treatment for hypopharyngeal squamous cell carcinoma, with a special focus on the evolution of an organ sparing paradigm. |
| doi_str_mv | 10.1016/j.oraloncology.2018.09.025 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2132224201</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1368837518303488</els_id><sourcerecordid>2132224201</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-7b3538723ce505bb845da01c41f049ddaa7e765ab693de79ef86c41a4ceb73123</originalsourceid><addsrcrecordid>eNqNkM1OwzAQhC0EolB4BRRx4pKwjuM47q0qP0WqxAXOluNs2lRpHOwU1LfHVQviyGlX2pkdzUfILYWEAs3v14l1urWdsa1d7pIUaJGATCDlJ-SCFkLGwCU7DTvLi7hggo_IpfdrAOCUwzkZMchAMhAXBOa73vYr7XbdEnUbGd0ZdJNoGvlBDxjZOhpWGGk3RA4_G_y6Ime1bj1eH-eYvD89vs3m8eL1-WU2XcQmy_IhFiXjrBApM8iBl2WR8UoDNRmtIZNVpbVAkXNd5pJVKCTWRR6OOjNYCkZTNiZ3h7-9sx9b9IPaNN5g2-oO7darlLI0TbNQPkgnB6lx1nuHtepdswmVFAW1J6bW6i8xtSemQKpALJhvjjnbcoPVr_UHURA8HAQY2gYCTnnTYKBUNQ7NoCrb_CfnG43qgsM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2132224201</pqid></control><display><type>article</type><title>Hypopharyngeal cancer: A state of the art review</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Garneau, Jonathan C. ; Bakst, Richard L. ; Miles, Brett A.</creator><creatorcontrib>Garneau, Jonathan C. ; Bakst, Richard L. ; Miles, Brett A.</creatorcontrib><description>•Hypopharyngeal squamous cell carcinoma has a reported 5-year overall survival rate of approximately 30–35%.•Nearly 50% of patients exhibitrecurrence within the first year after diagnosis.•Laryngeal preservation strategies are well supported although long term toxicity is significant.•Salvage surgery a common occurrence.•Future directions will focus on immunotherapy/targeted therapies to improve survival outcomes.
Cancer of the hypopharynx is relatively rare and accounts for roughly 3% of all head and neck cancers. Unfortunately, hypopharyngeal carcinoma has one of the worst prognosis of all head and neck cancers with a reported 5-year overall survival rate of approximately 30–35%. Toxicity related to therapy, and the need for surgical salvage continue to dominate the landscape in this disease. In this article, we set out to discuss a comprehensive overview of the current management principles, recent literature and evidence based therapeutic options surrounding treatment for hypopharyngeal squamous cell carcinoma, with a special focus on the evolution of an organ sparing paradigm.</description><identifier>ISSN: 1368-8375</identifier><identifier>EISSN: 1879-0593</identifier><identifier>DOI: 10.1016/j.oraloncology.2018.09.025</identifier><identifier>PMID: 30409307</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Clinical Trials as Topic ; Disease-Free Survival ; Head and neck squamous cell carcinoma ; Humans ; Hypopharyngeal cancer ; Hypopharyngeal carcinoma ; Hypopharyngeal Neoplasms - mortality ; Hypopharyngeal Neoplasms - therapy ; Hypopharynx - pathology ; Hypopharynx - radiation effects ; Hypopharynx - surgery ; Laryngeal preservation ; Larynx - radiation effects ; Neoplasm Recurrence, Local - epidemiology ; Neoplasm Recurrence, Local - prevention & control ; Organ Sparing Treatments - adverse effects ; Organ Sparing Treatments - methods ; Organs at Risk - radiation effects ; Prognosis ; Radiotherapy, Adjuvant - adverse effects ; Radiotherapy, Adjuvant - methods ; Review Literature as Topic ; Salvage Therapy - adverse effects ; Salvage Therapy - methods ; Squamous Cell Carcinoma of Head and Neck - mortality ; Squamous Cell Carcinoma of Head and Neck - therapy ; Survival Rate</subject><ispartof>Oral oncology, 2018-11, Vol.86, p.244-250</ispartof><rights>2018 Elsevier Ltd</rights><rights>Copyright © 2018 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-7b3538723ce505bb845da01c41f049ddaa7e765ab693de79ef86c41a4ceb73123</citedby><cites>FETCH-LOGICAL-c446t-7b3538723ce505bb845da01c41f049ddaa7e765ab693de79ef86c41a4ceb73123</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.oraloncology.2018.09.025$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30409307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Garneau, Jonathan C.</creatorcontrib><creatorcontrib>Bakst, Richard L.</creatorcontrib><creatorcontrib>Miles, Brett A.</creatorcontrib><title>Hypopharyngeal cancer: A state of the art review</title><title>Oral oncology</title><addtitle>Oral Oncol</addtitle><description>•Hypopharyngeal squamous cell carcinoma has a reported 5-year overall survival rate of approximately 30–35%.•Nearly 50% of patients exhibitrecurrence within the first year after diagnosis.•Laryngeal preservation strategies are well supported although long term toxicity is significant.•Salvage surgery a common occurrence.•Future directions will focus on immunotherapy/targeted therapies to improve survival outcomes.
Cancer of the hypopharynx is relatively rare and accounts for roughly 3% of all head and neck cancers. Unfortunately, hypopharyngeal carcinoma has one of the worst prognosis of all head and neck cancers with a reported 5-year overall survival rate of approximately 30–35%. Toxicity related to therapy, and the need for surgical salvage continue to dominate the landscape in this disease. In this article, we set out to discuss a comprehensive overview of the current management principles, recent literature and evidence based therapeutic options surrounding treatment for hypopharyngeal squamous cell carcinoma, with a special focus on the evolution of an organ sparing paradigm.</description><subject>Clinical Trials as Topic</subject><subject>Disease-Free Survival</subject><subject>Head and neck squamous cell carcinoma</subject><subject>Humans</subject><subject>Hypopharyngeal cancer</subject><subject>Hypopharyngeal carcinoma</subject><subject>Hypopharyngeal Neoplasms - mortality</subject><subject>Hypopharyngeal Neoplasms - therapy</subject><subject>Hypopharynx - pathology</subject><subject>Hypopharynx - radiation effects</subject><subject>Hypopharynx - surgery</subject><subject>Laryngeal preservation</subject><subject>Larynx - radiation effects</subject><subject>Neoplasm Recurrence, Local - epidemiology</subject><subject>Neoplasm Recurrence, Local - prevention & control</subject><subject>Organ Sparing Treatments - adverse effects</subject><subject>Organ Sparing Treatments - methods</subject><subject>Organs at Risk - radiation effects</subject><subject>Prognosis</subject><subject>Radiotherapy, Adjuvant - adverse effects</subject><subject>Radiotherapy, Adjuvant - methods</subject><subject>Review Literature as Topic</subject><subject>Salvage Therapy - adverse effects</subject><subject>Salvage Therapy - methods</subject><subject>Squamous Cell Carcinoma of Head and Neck - mortality</subject><subject>Squamous Cell Carcinoma of Head and Neck - therapy</subject><subject>Survival Rate</subject><issn>1368-8375</issn><issn>1879-0593</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkM1OwzAQhC0EolB4BRRx4pKwjuM47q0qP0WqxAXOluNs2lRpHOwU1LfHVQviyGlX2pkdzUfILYWEAs3v14l1urWdsa1d7pIUaJGATCDlJ-SCFkLGwCU7DTvLi7hggo_IpfdrAOCUwzkZMchAMhAXBOa73vYr7XbdEnUbGd0ZdJNoGvlBDxjZOhpWGGk3RA4_G_y6Ime1bj1eH-eYvD89vs3m8eL1-WU2XcQmy_IhFiXjrBApM8iBl2WR8UoDNRmtIZNVpbVAkXNd5pJVKCTWRR6OOjNYCkZTNiZ3h7-9sx9b9IPaNN5g2-oO7darlLI0TbNQPkgnB6lx1nuHtepdswmVFAW1J6bW6i8xtSemQKpALJhvjjnbcoPVr_UHURA8HAQY2gYCTnnTYKBUNQ7NoCrb_CfnG43qgsM</recordid><startdate>201811</startdate><enddate>201811</enddate><creator>Garneau, Jonathan C.</creator><creator>Bakst, Richard L.</creator><creator>Miles, Brett A.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201811</creationdate><title>Hypopharyngeal cancer: A state of the art review</title><author>Garneau, Jonathan C. ; Bakst, Richard L. ; Miles, Brett A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-7b3538723ce505bb845da01c41f049ddaa7e765ab693de79ef86c41a4ceb73123</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Clinical Trials as Topic</topic><topic>Disease-Free Survival</topic><topic>Head and neck squamous cell carcinoma</topic><topic>Humans</topic><topic>Hypopharyngeal cancer</topic><topic>Hypopharyngeal carcinoma</topic><topic>Hypopharyngeal Neoplasms - mortality</topic><topic>Hypopharyngeal Neoplasms - therapy</topic><topic>Hypopharynx - pathology</topic><topic>Hypopharynx - radiation effects</topic><topic>Hypopharynx - surgery</topic><topic>Laryngeal preservation</topic><topic>Larynx - radiation effects</topic><topic>Neoplasm Recurrence, Local - epidemiology</topic><topic>Neoplasm Recurrence, Local - prevention & control</topic><topic>Organ Sparing Treatments - adverse effects</topic><topic>Organ Sparing Treatments - methods</topic><topic>Organs at Risk - radiation effects</topic><topic>Prognosis</topic><topic>Radiotherapy, Adjuvant - adverse effects</topic><topic>Radiotherapy, Adjuvant - methods</topic><topic>Review Literature as Topic</topic><topic>Salvage Therapy - adverse effects</topic><topic>Salvage Therapy - methods</topic><topic>Squamous Cell Carcinoma of Head and Neck - mortality</topic><topic>Squamous Cell Carcinoma of Head and Neck - therapy</topic><topic>Survival Rate</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Garneau, Jonathan C.</creatorcontrib><creatorcontrib>Bakst, Richard L.</creatorcontrib><creatorcontrib>Miles, Brett A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Oral oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Garneau, Jonathan C.</au><au>Bakst, Richard L.</au><au>Miles, Brett A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hypopharyngeal cancer: A state of the art review</atitle><jtitle>Oral oncology</jtitle><addtitle>Oral Oncol</addtitle><date>2018-11</date><risdate>2018</risdate><volume>86</volume><spage>244</spage><epage>250</epage><pages>244-250</pages><issn>1368-8375</issn><eissn>1879-0593</eissn><abstract>•Hypopharyngeal squamous cell carcinoma has a reported 5-year overall survival rate of approximately 30–35%.•Nearly 50% of patients exhibitrecurrence within the first year after diagnosis.•Laryngeal preservation strategies are well supported although long term toxicity is significant.•Salvage surgery a common occurrence.•Future directions will focus on immunotherapy/targeted therapies to improve survival outcomes.
Cancer of the hypopharynx is relatively rare and accounts for roughly 3% of all head and neck cancers. Unfortunately, hypopharyngeal carcinoma has one of the worst prognosis of all head and neck cancers with a reported 5-year overall survival rate of approximately 30–35%. Toxicity related to therapy, and the need for surgical salvage continue to dominate the landscape in this disease. In this article, we set out to discuss a comprehensive overview of the current management principles, recent literature and evidence based therapeutic options surrounding treatment for hypopharyngeal squamous cell carcinoma, with a special focus on the evolution of an organ sparing paradigm.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>30409307</pmid><doi>10.1016/j.oraloncology.2018.09.025</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1368-8375 |
| ispartof | Oral oncology, 2018-11, Vol.86, p.244-250 |
| issn | 1368-8375 1879-0593 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2132224201 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Clinical Trials as Topic Disease-Free Survival Head and neck squamous cell carcinoma Humans Hypopharyngeal cancer Hypopharyngeal carcinoma Hypopharyngeal Neoplasms - mortality Hypopharyngeal Neoplasms - therapy Hypopharynx - pathology Hypopharynx - radiation effects Hypopharynx - surgery Laryngeal preservation Larynx - radiation effects Neoplasm Recurrence, Local - epidemiology Neoplasm Recurrence, Local - prevention & control Organ Sparing Treatments - adverse effects Organ Sparing Treatments - methods Organs at Risk - radiation effects Prognosis Radiotherapy, Adjuvant - adverse effects Radiotherapy, Adjuvant - methods Review Literature as Topic Salvage Therapy - adverse effects Salvage Therapy - methods Squamous Cell Carcinoma of Head and Neck - mortality Squamous Cell Carcinoma of Head and Neck - therapy Survival Rate |
| title | Hypopharyngeal cancer: A state of the art review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T19%3A01%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hypopharyngeal%20cancer:%20A%20state%20of%20the%20art%20review&rft.jtitle=Oral%20oncology&rft.au=Garneau,%20Jonathan%20C.&rft.date=2018-11&rft.volume=86&rft.spage=244&rft.epage=250&rft.pages=244-250&rft.issn=1368-8375&rft.eissn=1879-0593&rft_id=info:doi/10.1016/j.oraloncology.2018.09.025&rft_dat=%3Cproquest_cross%3E2132224201%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2132224201&rft_id=info:pmid/30409307&rft_els_id=S1368837518303488&rfr_iscdi=true |